The EMERALD trial is a double blind placebo clinical trial looking at the benefits of medicinal cannabis for MND. This is a study looking at the effects of a liquid form of medicinal cannabis in treating patients suffering with Amyotrophic Lateral Sclerosis (ALS) or Motor Neurone Disease (MND).
The study team are based at the Gold Coast University Hospital and aim to enrol 30 ALS patients over a 6-month period.
Participants in the study will receive either medicinal cannabis or placebo to evaluate protective mechanisms of cannabis that could help delay disease progression. Participants will also need to visit the clinic every 3 months and answer monthly telephone calls from the study team for the duration of the trial.
There may also be assistance available to help with transport and accommodation costs if needed.
Eligibility criteria:
- Patients with diagnosis of ALS/MND
- Aged between 25 and 80 years old
- With no significant respiratory issues
Please note: It is a legal requirement that all patients taking medicinal cannabis will not be allowed to drive any vehicle or operate dangerous machinery.
For further information, please contact:
Berzenn Urbi
Clinical Research Coordinator
Gold Coast University Hospital
Southport QLD 4215
P: +61 7 5687 6476
M: +61417 221 342
F: 07 5687 7850
E:
Web: www.goldcoast.health.qld.gov.au
Or download the brochure of information here: